Skip to main navigation Skip to search Skip to main content

Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial

  • Dominantly Inherited Alzheimer's Disease–Trials Unit

Research output: Contribution to journal › Article › peer-review

27   Link opens in a new tab Citations (Scopus)

Fingerprint

Dive into the research topics of 'Safety and efficacy of long-term gantenerumab treatment in dominantly inherited Alzheimer's disease: an open-label extension of the phase 2/3 multicentre, randomised, double-blind, placebo-controlled platform DIAN-TU trial'. Together they form a unique fingerprint.
Sort by

Keyphrases

Medicine and Dentistry

Pharmacology, Toxicology and Pharmaceutical Science